Bio-Path Holdings to Host Corporate Update Conference Call on May 29, 2025

Bio-Path Holdings, Inc. (OTCQB: BPTH), a biotechnology firm based in Houston, is set to host a corporate update conference call on May 29, 2025, at 8:30 a.m. ET. This event will provide investors and interested parties with a detailed overview of the company’s business activities and advancements. Participants can join the call by dialing (844) 481-3014 for domestic calls or (412) 317-1879 for international inquiries. An audio webcast will also be accessible through the Presentations section of Bio-Path's official website, with an archive available post-event.

Bio-Path Holdings focuses on its proprietary DNAbilize® technology, which facilitates the development of RNAi nanoparticle drugs designed to target cancer and obesity therapies through simple intravenous infusions. The company's lead product, prexigebersen (BP1001), is currently undergoing a Phase 2 clinical trial aimed at treating blood cancers. A modified version, BP1001-A, is in a Phase 1/1b study for solid tumors and is also being explored for obesity treatments among Type 2 diabetes patients.

Additionally, Bio-Path’s second product candidate, BP1002, targets the Bcl-2 protein and is being researched for a range of cancers, including acute myeloid leukemia. The company also anticipates filing an Investigational New Drug (IND) application for BP1003, a newly developed STAT3 antisense oligodeoxynucleotide, characterized by a unique liposome incorporation to enhance efficacy.

Bio-Path Holdings continues to innovate in the fight against cancer and obesity, with several promising therapies in the pipeline. For further information, interested parties can explore the company’s website or contact investor relations representatives.

As Bio-Path Holdings, Inc. prepares to host a corporate update conference call on May 29, 2025, investors should view this opportunity as a critical moment to reassess the company's strategic direction and its market potential. The conference call will likely provide insights into the progress of its innovative DNAbilize® antisense RNAi nanoparticle technology, which has applications in both oncology and obesity treatment, appealing to a broad spectrum of investors.

The upcoming call comes at a significant juncture for Bio-Path, with the lead candidate, prexigebersen (BP1001), advancing in Phase 2 trials for blood cancers and showing promise in the obesity domain through BP1001-A. This dual focus not only enhances the company’s portfolio but also mitigates risk since it diversifies target markets and treatment modalities. Furthermore, the anticipated filing of an IND application for BP1003 demonstrates Bio-Path’s commitment to advancing its drug pipeline and serving unmet medical needs, particularly within the oncology space.

Investors should closely monitor the development timelines discussed during the call, as milestones achieved can affect stock valuations substantially. A successful report could catalyze price momentum, especially if key partnerships or collaborations are announced or if clinical trial results demonstrate improved efficacy.

Furthermore, with competition in the biotechnology sector ramping up, investors must consider Bio-Path’s unique selling propositions and the scalability of its technologies. The company’s financial health, funding avenues, and any potential FDA feedback can also influence immediate market reactions.

Overall, stakeholders should leverage the insights gained from the conference to evaluate potential buy or hold strategies, understanding that investing in biotechnology carries inherent volatility but offers significant upside potential for those willing to embrace the associated risks.